TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PILOCARPINE HYDROCHLORIDE

PILOCARPINE HYDROCHLORIDE
Oncology Approved 2004-11-16
10
Indications
--
Phase 3 Trials
21
Years on Market

Details

Status
Prescription
First Approved
2004-11-16
Routes
OPHTHALMIC, ORAL
Dosage Forms
SOLUTION/DROPS, TABLET

PILOCARPINE HYDROCHLORIDE Approval History

Loading approval history...

What PILOCARPINE HYDROCHLORIDE Treats

4 indications

PILOCARPINE HYDROCHLORIDE is approved for 4 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dry Mouth
  • Salivary Gland Hypofunction
  • Head and Neck Cancer
  • Sjogren's Syndrome
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PILOCARPINE HYDROCHLORIDE FDA Label Details

Pro

Indications & Usage

: Pilocarpine hydrochloride tablets, USP are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.